Moderna Inc (MRNA) stock has risen 390.90% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives MRNA stock a score of 66 out of a possible 100.
That rank is primarily influenced by a long-term technical score of 96. MRNA's rank also includes a short-term technical score of 89. The fundamental score for MRNA is 12. In addition to the average rating from Wall Street analysts, MRNA stock has a mean target price of 89.583. This means analysts expect the stock to lose 6.18% over the next 12 months.
What's Happening with MRNA Stock Today
Moderna Inc (MRNA) stock has gained 6.81% while the S&P 500 has risen 1.13% as of 11:38 AM on Monday, Nov 16. MRNA has risen $6.09 from the previous closing price of $89.39 on volume of 44,694,031 shares. Over the past year the S&P 500 has risen 16.14% while MRNA has risen 390.90%. MRNA lost -$1.62 per share in the over the last 12 months.